Selected research
Industry Research
Obesity Diagnosis and Treatment Industry Research Report 2026
Market perspective
The global Obesity Diagnosis and Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Obesity Diagnosis and Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Obesity Diagnosis and Treatment market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Obesity Diagnosis and Treatment market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Obesity Diagnosis and Treatment include Obesity diagnosis and treatment, GlaxoSmithKline, Arena Pharmaceuticals, Pfizer, Allergan, Obalon Therapeutics, Nalpropion Pharmaceuticals, Novo Nordisk and Beijing Noble Laser Technology, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Obesity Diagnosis and Treatment market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Obesity Diagnosis and Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Obesity Diagnosis and Treatment Market by Company
Obesity diagnosis and treatment
GlaxoSmithKline
Arena Pharmaceuticals
Pfizer
Allergan
Obalon Therapeutics
Nalpropion Pharmaceuticals
Novo Nordisk
Beijing Noble Laser Technology
Eisai
Orexigen Therapeutics
ReShape Lifesciences
Roche
Allurion Technologies
Medtronic
VIVUS
ApolloEndosurgery
Ethicon, Inc.
AstraZeneca
Takeda Pharmaceutical Company
Currax Pharmaceuticals
Obesity Diagnosis and Treatment Segment by Type
Medication
Surgery
Fitness
Others
Obesity Diagnosis and Treatment Segment by Application
<18 Years Old
18-35 Years Old
36-45 Years Old
45-55 Years Old
>55 Years Old
Obesity Diagnosis and Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Obesity Diagnosis and Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Obesity Diagnosis and Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Obesity Diagnosis and Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Obesity Diagnosis and Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Medication
- Surgery
- Fitness
- Others
Applications
- <18 Years Old
- 18-35 Years Old
- 36-45 Years Old
- 45-55 Years Old
- >55 Years Old
Companies covered
- Obesity diagnosis and treatment
- GlaxoSmithKline
- Arena Pharmaceuticals
- Pfizer
- Allergan
- Obalon Therapeutics
- Nalpropion Pharmaceuticals
- Novo Nordisk
- Beijing Noble Laser Technology
- Eisai
- Orexigen Therapeutics
- ReShape Lifesciences
- Roche
- Allurion Technologies
- Medtronic
- VIVUS
- ApolloEndosurgery
- Ethicon, Inc.
- AstraZeneca
- Takeda Pharmaceutical Company
- Currax Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Obesity Diagnosis and Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Medication
- 2.2.3 Surgery
- 2.2.4 Fitness
- 2.2.5 Others
- 2.3 Obesity Diagnosis and Treatment by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 <18 Years Old
- 2.3.3 18-35 Years Old
- 2.3.4 36-45 Years Old
- 2.3.5 45-55 Years Old
- 2.3.6 >55 Years Old
- 2.4 Assumptions and Limitations
3 Obesity Diagnosis and Treatment Breakdown Data by Type
- 3.1 Global Obesity Diagnosis and Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global Obesity Diagnosis and Treatment Forecasted Market Size by Type (2027-2032)
4 Obesity Diagnosis and Treatment Breakdown Data by Application
- 4.1 Global Obesity Diagnosis and Treatment Historic Market Size by Application (2021-2026)
- 4.2 Global Obesity Diagnosis and Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Obesity Diagnosis and Treatment Market Perspective (2021-2032)
- 5.2 Global Obesity Diagnosis and Treatment Growth Trends by Region
- 5.2.1 Global Obesity Diagnosis and Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Obesity Diagnosis and Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Obesity Diagnosis and Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Obesity Diagnosis and Treatment Market Dynamics
- 5.3.1 Obesity Diagnosis and Treatment Industry Trends
- 5.3.2 Obesity Diagnosis and Treatment Market Drivers
- 5.3.3 Obesity Diagnosis and Treatment Market Challenges
- 5.3.4 Obesity Diagnosis and Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Obesity Diagnosis and Treatment Players by Revenue
- 6.1.1 Global Top Obesity Diagnosis and Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Obesity Diagnosis and Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Obesity Diagnosis and Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Obesity Diagnosis and Treatment Head Office and Area Served
- 6.4 Global Obesity Diagnosis and Treatment Players, Product Type & Application
- 6.5 Global Obesity Diagnosis and Treatment Manufacturers Established Date
- 6.6 Global Obesity Diagnosis and Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Obesity Diagnosis and Treatment Market Size (2021-2032)
- 7.2 North America Obesity Diagnosis and Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Obesity Diagnosis and Treatment Market Size by Country (2021-2026)
- 7.4 North America Obesity Diagnosis and Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Obesity Diagnosis and Treatment Market Size (2021-2032)
- 8.2 Europe Obesity Diagnosis and Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Obesity Diagnosis and Treatment Market Size by Country (2021-2026)
- 8.4 Europe Obesity Diagnosis and Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Obesity Diagnosis and Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Obesity Diagnosis and Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Obesity Diagnosis and Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Obesity Diagnosis and Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Obesity Diagnosis and Treatment Market Size (2021-2032)
- 10.2 South America Obesity Diagnosis and Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Obesity Diagnosis and Treatment Market Size by Country (2021-2026)
- 10.4 South America Obesity Diagnosis and Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Obesity Diagnosis and Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Obesity Diagnosis and Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Obesity Diagnosis and Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Obesity Diagnosis and Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Obesity diagnosis and treatment
- 12.1.1 Obesity diagnosis and treatment Company Information
- 12.1.2 Obesity diagnosis and treatment Business Overview
- 12.1.3 Obesity diagnosis and treatment Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.1.4 Obesity diagnosis and treatment Obesity Diagnosis and Treatment Product Portfolio
- 12.1.5 Obesity diagnosis and treatment Recent Developments
- 12.2 GlaxoSmithKline
- 12.2.1 GlaxoSmithKline Company Information
- 12.2.2 GlaxoSmithKline Business Overview
- 12.2.3 GlaxoSmithKline Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.2.4 GlaxoSmithKline Obesity Diagnosis and Treatment Product Portfolio
- 12.2.5 GlaxoSmithKline Recent Developments
- 12.3 Arena Pharmaceuticals
- 12.3.1 Arena Pharmaceuticals Company Information
- 12.3.2 Arena Pharmaceuticals Business Overview
- 12.3.3 Arena Pharmaceuticals Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.3.4 Arena Pharmaceuticals Obesity Diagnosis and Treatment Product Portfolio
- 12.3.5 Arena Pharmaceuticals Recent Developments
- 12.4 Pfizer
- 12.4.1 Pfizer Company Information
- 12.4.2 Pfizer Business Overview
- 12.4.3 Pfizer Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.4.4 Pfizer Obesity Diagnosis and Treatment Product Portfolio
- 12.4.5 Pfizer Recent Developments
- 12.5 Allergan
- 12.5.1 Allergan Company Information
- 12.5.2 Allergan Business Overview
- 12.5.3 Allergan Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.5.4 Allergan Obesity Diagnosis and Treatment Product Portfolio
- 12.5.5 Allergan Recent Developments
- 12.6 Obalon Therapeutics
- 12.6.1 Obalon Therapeutics Company Information
- 12.6.2 Obalon Therapeutics Business Overview
- 12.6.3 Obalon Therapeutics Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.6.4 Obalon Therapeutics Obesity Diagnosis and Treatment Product Portfolio
- 12.6.5 Obalon Therapeutics Recent Developments
- 12.7 Nalpropion Pharmaceuticals
- 12.7.1 Nalpropion Pharmaceuticals Company Information
- 12.7.2 Nalpropion Pharmaceuticals Business Overview
- 12.7.3 Nalpropion Pharmaceuticals Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.7.4 Nalpropion Pharmaceuticals Obesity Diagnosis and Treatment Product Portfolio
- 12.7.5 Nalpropion Pharmaceuticals Recent Developments
- 12.8 Novo Nordisk
- 12.8.1 Novo Nordisk Company Information
- 12.8.2 Novo Nordisk Business Overview
- 12.8.3 Novo Nordisk Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.8.4 Novo Nordisk Obesity Diagnosis and Treatment Product Portfolio
- 12.8.5 Novo Nordisk Recent Developments
- 12.9 Beijing Noble Laser Technology
- 12.9.1 Beijing Noble Laser Technology Company Information
- 12.9.2 Beijing Noble Laser Technology Business Overview
- 12.9.3 Beijing Noble Laser Technology Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.9.4 Beijing Noble Laser Technology Obesity Diagnosis and Treatment Product Portfolio
- 12.9.5 Beijing Noble Laser Technology Recent Developments
- 12.10 Eisai
- 12.10.1 Eisai Company Information
- 12.10.2 Eisai Business Overview
- 12.10.3 Eisai Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.10.4 Eisai Obesity Diagnosis and Treatment Product Portfolio
- 12.10.5 Eisai Recent Developments
- 12.11 Orexigen Therapeutics
- 12.11.1 Orexigen Therapeutics Company Information
- 12.11.2 Orexigen Therapeutics Business Overview
- 12.11.3 Orexigen Therapeutics Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.11.4 Orexigen Therapeutics Obesity Diagnosis and Treatment Product Portfolio
- 12.11.5 Orexigen Therapeutics Recent Developments
- 12.12 ReShape Lifesciences
- 12.12.1 ReShape Lifesciences Company Information
- 12.12.2 ReShape Lifesciences Business Overview
- 12.12.3 ReShape Lifesciences Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.12.4 ReShape Lifesciences Obesity Diagnosis and Treatment Product Portfolio
- 12.12.5 ReShape Lifesciences Recent Developments
- 12.13 Roche
- 12.13.1 Roche Company Information
- 12.13.2 Roche Business Overview
- 12.13.3 Roche Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.13.4 Roche Obesity Diagnosis and Treatment Product Portfolio
- 12.13.5 Roche Recent Developments
- 12.14 Allurion Technologies
- 12.14.1 Allurion Technologies Company Information
- 12.14.2 Allurion Technologies Business Overview
- 12.14.3 Allurion Technologies Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.14.4 Allurion Technologies Obesity Diagnosis and Treatment Product Portfolio
- 12.14.5 Allurion Technologies Recent Developments
- 12.15 Medtronic
- 12.15.1 Medtronic Company Information
- 12.15.2 Medtronic Business Overview
- 12.15.3 Medtronic Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.15.4 Medtronic Obesity Diagnosis and Treatment Product Portfolio
- 12.15.5 Medtronic Recent Developments
- 12.16 VIVUS
- 12.16.1 VIVUS Company Information
- 12.16.2 VIVUS Business Overview
- 12.16.3 VIVUS Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.16.4 VIVUS Obesity Diagnosis and Treatment Product Portfolio
- 12.16.5 VIVUS Recent Developments
- 12.17 ApolloEndosurgery
- 12.17.1 ApolloEndosurgery Company Information
- 12.17.2 ApolloEndosurgery Business Overview
- 12.17.3 ApolloEndosurgery Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.17.4 ApolloEndosurgery Obesity Diagnosis and Treatment Product Portfolio
- 12.17.5 ApolloEndosurgery Recent Developments
- 12.18 Ethicon, Inc.
- 12.18.1 Ethicon, Inc. Company Information
- 12.18.2 Ethicon, Inc. Business Overview
- 12.18.3 Ethicon, Inc. Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.18.4 Ethicon, Inc. Obesity Diagnosis and Treatment Product Portfolio
- 12.18.5 Ethicon, Inc. Recent Developments
- 12.19 AstraZeneca
- 12.19.1 AstraZeneca Company Information
- 12.19.2 AstraZeneca Business Overview
- 12.19.3 AstraZeneca Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.19.4 AstraZeneca Obesity Diagnosis and Treatment Product Portfolio
- 12.19.5 AstraZeneca Recent Developments
- 12.20 Takeda Pharmaceutical Company
- 12.20.1 Takeda Pharmaceutical Company Company Information
- 12.20.2 Takeda Pharmaceutical Company Business Overview
- 12.20.3 Takeda Pharmaceutical Company Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.20.4 Takeda Pharmaceutical Company Obesity Diagnosis and Treatment Product Portfolio
- 12.20.5 Takeda Pharmaceutical Company Recent Developments
- 12.21 Currax Pharmaceuticals
- 12.21.1 Currax Pharmaceuticals Company Information
- 12.21.2 Currax Pharmaceuticals Business Overview
- 12.21.3 Currax Pharmaceuticals Revenue in Obesity Diagnosis and Treatment Business (2021-2026)
- 12.21.4 Currax Pharmaceuticals Obesity Diagnosis and Treatment Product Portfolio
- 12.21.5 Currax Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst